Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Somatic mutations predict risk of invasive fungal disease in patients with acute myeloid leukemia treated with intensive induction chemotherapy

Archana Sasi, Victor Kovac, Yiwen Liu, Jessica Little, Ann Woolley, Harrison Tsai, Vincent Ho, Shai Shimony, Eric Winer, Richard Stone, Daniel Deangelo, Marlise Luskin, Lindsey Baden, R. Coleman Lindsley, Rahul Vedula

Blood (2025) 146 (Supplement 1): 5180.

https://doi.org/10.1182/blood-2025-5180

Published: 2025

Journal Articles

Hypomethylating agent with venetoclax versus hypomethylating agent alone in frontline management of myelodysplastic syndrome - impact of subgroups on clinical outcomes

Blood (2025) 146 (Supplement 1): 239.

https://doi.org/10.1182/blood-2025-239

Published: 2025

Journal Articles

Prognosis in adults with ph-positive B-ALL in first complete remission without minimal residual disease after blinatumomab consolidation is influenced by minimal residual disease (≥10-4) pre-blinatumomab

Blood (2025) 146 (Supplement 1): 3329.

https://doi.org/10.1182/blood-2025-3329

Published: 2025

Journal Articles

Myeloid malignancies molecular analysis for therapy choice (myeloMATCH): Rapid availability of clinical, pathologic and molecular features for treatment assignment in the first 550 patients.

Blood (2025) 146 (Supplement 1): 5279.

https://doi.org/10.1182/blood-2025-5279

Published: 2025

Journal Articles

Updated response and safety analyses from a Phase 1 study of ivosidenib combined with intensive chemotherapy in patients with newly diagnosed (ND) Acute Myeloid Leukemia with isocitrate dehydrogenase (IDH)1 mutation

Blood (2025) 146 (Supplement 1): 992.

https://doi.org/10.1182/blood-2025-992

Published: 2025

Journal Articles

Real-world practice patterns of IDH inhibitors and outcomes of on-label IDH inhibitor use for Acute Myeloid Leukemia in the United States

Blood (2025) 146 (Supplement 1): 1614.

https://doi.org/10.1182/blood-2025-1614

Published: 2025

Journal Articles

Temporal multiomic profiling reveals intrinsic resistance mechanisms to ERK inhibition in relapsed Acute Myeloid Leukemia

Rahul Vedula, Hannah Karp, Danielle Morrow, Andrew Gehrke, Yiwen Liu, Ellen Weisberg, Carter Lombardi, Rebecca Leonard, Ilene Galinsky, Jacqueline Garcia, Marlise Luskin, Maximilian Stahl, Martha Wadleigh, Eric Winer, Daniel Deangelo, James Griffin, Richard Stone, R. Coleman Lindsley

Blood (2025) 146 (Supplement 1): 3265.

https://doi.org/10.1182/blood-2025-3265

Published: 2025

Journal Articles

Venetoclax plus inotuzumab ozogamicin for relapsed and refractory ALL: Results of a phase I trial

Marlise Luskin, Julia Keating, Benjamin Frost, Yael Flamand, Jacqueline Garcia, Richard Stone, Rebecca Leonard, Stella Jaeckle, Chase Weizer, Jessica Lee, Ilene Galinsky, Jeremy Ryan, Eric Winer, Evan Chen, Anthony Letai, Mark Murakami, Daniel Deangelo

Blood (2025) 146 (Supplement 1): 645.

https://doi.org/10.1182/blood-2025-645

Published: 2025

Journal Articles

Corticosteroids Plus Intravenous Immune Globulin (IVIg) Versus Corticosteroids Alone In The Treatment Of Newly Diagnosed Primary Immune Thrombocytopenia In Adults: A Retrospective Study

Alina M Huang, MD, Eric Winer, MD, Jorge J Castillo, MD, Andrew Foderaro, MD

Blood (2013) 122 (21): 4748.

https://doi.org/10.1182/blood.V122.21.4748.4748

Published: 2013

Journal Articles

Survival of Newly Diagnosed T-Cell Lymphoma (TCL) in the Modern Era: Investigation of Prognostic Factors with Critical Examination of Therapy in a Multicenter US Cohort.

Blood (2012) 120 (21): 2728.

https://doi.org/10.1182/blood.V120.21.2728.2728

Published: 2012

Journal Articles

Short Course of Bendamustine and Rituximab Followed by 90Y-Ibritumomab Tiuxetan in Patients with Chemotherapy-Naïve Follicular Lymphoma: Early Results of “Fol-Brite”

Frederick Lansigan, MD, Eric Winer, MD, Sara R Metzler, RN, Lynn Shaw, RN, Peggy Alton, RN, Kate Foster, MPH, Todd MacKenzie, PhD, Anne W Beaven, MD

Blood (2012) 120 (21): 3657.

https://doi.org/10.1182/blood.V120.21.3657.3657

Published: 2012

Journal Articles

Weekly Combination Chemotherapy with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for Newly Diagnosed Patients with Advanced Cardiac Disease Due to Systemic AL Amyloidosis

Furha I. Cossor, MD, Adam Boruchov, MD, Michael Danso, MD, Michael Edward Lee, Ayan Patel, MD, Eric Winer, MD, Rodney Falk, MD, Raymond L. Comenzo, MD

Blood (2011) 118 (21): 5139.

https://doi.org/10.1182/blood.V118.21.5139.5139

Published: 2011

Journal Articles

Proton Pump Inhibitor Use and the Ability to Replete Iron Stores

Alina M Huang, MD, Christine M Ho, MD, John L. Reagan, MD, Eric Winer, MD

Blood (2011) 118 (21): 1039.

https://doi.org/10.1182/blood.V118.21.1039.1039

Published: 2011

Journal Articles

Phase I Trial Examining Addition of Gemcitabine to CHOP in Intermediate Grade NHL.

John L. Reagan, MD, James N. Butera, MD, Alan G. Rosmarin, MD, Ahmed Nadeem, MD, Fred J. Schiffman, MD, William Sikov, MD, Eric Winer, MD, Anthony Mega, MD

Blood (2009) 114 (22): 4765.

https://doi.org/10.1182/blood.V114.22.4765.4765

Published: 2009

Journal Articles

Non-Engraftment Haploidentical Cellular Immunotherapy for Refractory Malignancies: Tumor Responses without Chimerism

Gerald A. Colvin, DO, David Berz, Muthalagu Ramanathan, MD, Eric Winer, MD, Loren D. Fast, PhD, Gerald Jay Elfenbein, MD, Peter J. Quesenberry, MD

Blood (2008) 112 (11): 831.

https://doi.org/10.1182/blood.V112.11.831.831

Published: 2008

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Somatic mutations predict risk of invasive fungal disease in patients with acute myeloid leukemia treated with intensive induction chemotherapy

Hypomethylating agent with venetoclax versus hypomethylating agent alone in frontline management of myelodysplastic syndrome - impact of subgroups on clinical outcomes

Prognosis in adults with ph-positive B-ALL in first complete remission without minimal residual disease after blinatumomab consolidation is influenced by minimal residual disease (≥10-4) pre-blinatumomab

Myeloid malignancies molecular analysis for therapy choice (myeloMATCH): Rapid availability of clinical, pathologic and molecular features for treatment assignment in the first 550 patients.

Updated response and safety analyses from a Phase 1 study of ivosidenib combined with intensive chemotherapy in patients with newly diagnosed (ND) Acute Myeloid Leukemia with isocitrate dehydrogenase (IDH)1 mutation

Real-world practice patterns of IDH inhibitors and outcomes of on-label IDH inhibitor use for Acute Myeloid Leukemia in the United States

Temporal multiomic profiling reveals intrinsic resistance mechanisms to ERK inhibition in relapsed Acute Myeloid Leukemia

Venetoclax plus inotuzumab ozogamicin for relapsed and refractory ALL: Results of a phase I trial

Corticosteroids Plus Intravenous Immune Globulin (IVIg) Versus Corticosteroids Alone In The Treatment Of Newly Diagnosed Primary Immune Thrombocytopenia In Adults: A Retrospective Study

Survival of Newly Diagnosed T-Cell Lymphoma (TCL) in the Modern Era: Investigation of Prognostic Factors with Critical Examination of Therapy in a Multicenter US Cohort.

Short Course of Bendamustine and Rituximab Followed by 90Y-Ibritumomab Tiuxetan in Patients with Chemotherapy-Naïve Follicular Lymphoma: Early Results of “Fol-Brite”

Weekly Combination Chemotherapy with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for Newly Diagnosed Patients with Advanced Cardiac Disease Due to Systemic AL Amyloidosis

Proton Pump Inhibitor Use and the Ability to Replete Iron Stores

Phase I Trial Examining Addition of Gemcitabine to CHOP in Intermediate Grade NHL.

Non-Engraftment Haploidentical Cellular Immunotherapy for Refractory Malignancies: Tumor Responses without Chimerism

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only